Ratcliffe Liam 4

What Happened

• Liam Ratcliffe, a director of OnKure Therapeutics, was granted an award of 1,275 derivative shares (reported as an "A" award/option acquisition) on 2026-06-04. The grant was reported at $0.00 per share (no cash paid) and therefore has no immediate purchase value.

Key Details

• Transaction date: 2026-06-04; Form 4 filed: 2026-06-08 (filed on a timely basis).
• Reported amount: 1,275 derivative shares; reported price: $0.00 (Acquired).
• Shares owned after transaction: Not specified in the filing.
• Footnote: The award is an option that will vest 100% on the earlier of June 4, 2027 or the day prior to the issuer’s next annual meeting, subject to continued service.
• No indication of an immediate sale, cashless exercise, tax withholding, or 10b5-1 plan in this filing.

Context

• This is a compensation-related grant (an option/award) to a director, common for non-employee directors and does not reflect an immediate market purchase or sale. The award vests in the future if the director remains a service provider, meaning potential ownership is contingent on continued service and future vesting.